LA JOLLA, Calif.--(BUSINESS WIRE)--Nov. 29, 2021--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the expansion and branding of its translational medicine service offering, DermTech Stratum™, which utilizes DermTech’s non-invasive technology and precision biomarker approaches to bring heightened precision and personalization to dermatologic disease diagnosis and treatment development. This broadened service offering leverages DermTech’s proprietary platform technology for biomarker analysis of RNA, DNA, protein and microbiome.
DermTech’s non-invasive Smart Sticker™ is used to painlessly collect cellular material from the surface of a patient’s skin for precision genomic and proteomic analysis. DermTech Stratum offers the opportunity for research partners and collaborators to non-invasively collect skin samples for analysis to identify biomarkers of disease and subgroups of disease, stratify patients based on genomic and proteomic profiles, enrich for responders in a population and predict and track responses to therapeutic intervention.
DermTech Stratum includes expert services such as biomarker identification, new target identification, patient segmentation and stratification, and bioinformatics support. The DermTech Stratum service offering is appropriate for indications where skin is the target or a surrogate target organ and are being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research studies.
“DermTech is continuing to pave the way for continued innovation in precision and personalized dermatology,” said Michael Howell, chief scientific officer of DermTech. “With a goal of helping to advance diagnostic tools and treatments to improve skin health, we are proud to introduce DermTech Stratum to the market.”
The DermTech Smart Sticker™ provides a 19mm collection area for lesional and non-lesional samples, collecting 1.5mg of stratum corneum tissue, eliminating the need for surgical biopsies in clinical research studies. Once collected, the sample does not require fixation or refrigeration and preserves genomic and proteomic material from the skin for up to 10 days at room temperature and more than a year when stored at -80 C.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, benefits to research partners and collaborators, cost-effectiveness, commercialization and adoption of DermTech’s products and services and the market opportunity therefor, and DermTech’s ability to expand its product and service offerings. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products and services; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005678/en/
Source: DermTech, Inc.